ArticleInternational journal of clinical pediatric dentistry2025
Adverse Events of 4% Articaine in Children below 4 Years of Age: An Observational Study.
Article in International journal of clinical pediatric dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim and background: The use of articaine is well documented in children aged 4 years and above. However, there is a paucity of data concerning its use in children younger than 4 years of age. This study observed the type and severity of adverse events (AEs) that could occur with the use of 4% articaine with 1:1,00,000 epinephrine for supraperiosteal injections in children below 4 years of age. Materials and methods: About 30 children fulfilling the inclusion criteria, requiring supraperiosteal injections for procedures in posterior primary teeth, were observed postinjection of the drug. The procedures that followed the drug administration were classified as "simple" or "complex." The "type and severity" of the AEs observed were documented according to the methodology by Kalenderian. The World Health Organization-Uppsala Monitoring Centre (WHO-UMC) scale was utilized for the "causality" assessment of the drug. The "preventability" of the AEs was assessed using the modified Schumock and Thornton scale. AEs occurring in "<5 minutes," "until 60 minutes," and "up to 24 hours" were recorded. Descriptive statistics and cross-tabulations were done using Pearson's Chi-squared test, with significance set at Results: Three children (23.1%) reported pain in the observation time interval "until 60 minutes". These children had undergone procedures that were classified as "complex." The Conclusion: The findings of this study, within the sample size studied, did not find any AE directly linked to 4% articaine hydrochloride with 1:1,00,000 epinephrine during supraperiosteal injections in children below 4 years of age. Clinical significance: Articaine is not advocated for clinical use in children below 4 years of age. This study addresses the important clinical question of "whether articaine can be safely used in children under 4 years of age for supraperiosteal injections?" How to cite this article: Ananthu H, Rao AP, Kamath A,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.